Collegium Pharmaceutical (COLL) Gains from Investment Securities (2024 - 2025)
Collegium Pharmaceutical (COLL) posted quarterly Gains from Investment Securities of -$19000.0 for Q4 2025, up 99.35% year-over-year from -$9531.1 in Q4 2024, and little changed quarter-over-quarter from -$19000.0 in Q3 2025.
Collegium Pharmaceutical (COLL) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Collegium Pharmaceutical's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$19000.0 for Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 99.35% year-over-year to -$19000.0; the TTM figure through Mar 2026 stood at -$396000.0 (up 89.3% YoY), while the FY2025 annual figure was -$1.2 million, up 59.44% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$19000.0, roughly flat from -$19000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was -$19000.0 in Q3 2025, with the low at -$2.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Collegium Pharmaceutical | 897.05 Mn | 747.74 Mn | 110.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19,000.00 |
| Dec 31, 2025 | -19,000.00 |
| Sep 30, 2025 | -19,000.00 |
| Sep 30, 2025 | -19,000.00 |
| Jun 30, 2025 | -358,000.00 |
| Jun 30, 2025 | -358,000.00 |
| Mar 31, 2025 | -786,000.00 |
| Mar 31, 2025 | -786,000.00 |
| Dec 31, 2024 | -2.91 Mn |
| Dec 31, 2024 | -2.91 Mn |